Clinical trial · Observational
Radiology Registry on Pancreatic Malignancies
NCT05714111CI-TRIAL-00076021RadonPamsrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
The purpose of this study is to collect all radiological data which evaluated with clinical data may help assess malignancy and prognosis of pancreatic disease.This registry aims to collect retrospective data from 2014 and prospective data until 2027 with a maximum follow-up of 3 years per patient.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Cyst | — | UNRESOLVED | — |
| Pancreas Disease | — | UNRESOLVED | — |
| Pancreas Neoplasm | Pancreatic Neoplasm | ALIAS | 0.90 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiology evaluations and interventions | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Progression- free survival
- timeFrame
- From date of intervention until the date of first documented progression, up to a maximum of 3 years
- description
- Time from start of observation to disease progression
- measure
- Local progression free survival
- timeFrame
- From date of intervention until the date of first documented local progression assessed up to a maximum of 3 years
- description
- Time between (start of) a locoregional treatment and local disease progression
Secondary outcomes (1)
- measure
- Overall Survival
- timeFrame
- From date of treatment until the date of death from any cause assessed up to 3 years
- description
- The length of time from either the date of diagnosis or the start of treatment for a disease, in which the patients are still alive
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ≥18 years of age * Patients with suspect (planned for investigation) or diagnosed pancreatic cancer at any stage. * able and willing to sign informed consent Exclusion Criteria: * Patients with non-primary pancreatic disease
References
Publications (0)
Data not yet available
No reference posted for this study.